Kazakhstan to Build Four New Pharmaceutical Plants Under Presidential Directives
Kazakhstan is set to construct four new pharmaceutical manufacturing plants as part of the directives issued by President Kassym Jomart Tokayev to increase the share of domestic production in the pharmaceutical sector.
The Government has approved investment agreements between the Ministry of Healthcare and four companies: AltINFARM, MSP ROMPHARM, Abdi Ibrahim Global Pharm, and Nobel Almaty Pharmaceutical Factory. The total investment volume for the approved projects amounts to 173 billion tenge. The relevant resolutions were signed by Prime Minister Olzhas Bektenov.
The projects aim to localize the production of 356 types of medicines, including socially significant drugs. The planned product range covers treatments for oncology and diabetes, as well as immunobiological, antiviral, anti anemic, analgesic, anti inflammatory, cold and antimicrobial medicines.
New production facilities will be located in Almaty (two projects), Turkistan Region, and Almaty Region. Overall, around 675 new jobs are expected to be created.
One of the largest projects will be implemented by AltINFARM, which plans to build a pharmaceutical plant in the Innovation Technology Park special economic zone in Almaty, with investments of 58.5 billion tenge. The plant will produce 54 medicines, including 35 socially significant ones, in partnership with Sinopharm, Sinovac, and Kangtai Biological Technology.
Nobel Almaty Pharmaceutical Factory will also build a GMP compliant complex in Almaty for active pharmaceutical ingredients, medicines, and biopharmaceuticals, investing 39.2 billion tenge and creating at least 200 jobs.
Abdi Ibrahim Global Pharm will establish a multi profile pharmaceutical complex in Almaty Region with investments of 39 billion tenge, while MSP ROMPHARM plans to build a high tech plant in the TURAN special economic zone in Turkistan Region, investing 36.7 billion tenge.
The implementation of these projects is expected to significantly reduce import dependence, strengthen pharmaceutical security, and ensure stable access to affordable domestically produced medicines for the population.
